The role of CD36 receptor in the pathogenesis of atherosclerosis

Advances in Clinical and Experimental Medicine

Volumn 26, Issue 4, 2017, Pages 717-722

  Choromañska, Barbara ^a   Mysliwiec, Piotr ^a   Choromañska, Katarzyna ^a   Dadan, Jacek ^a   Chabowski, Adrian ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Atherosclerosis; Cd36 Receptor; Ox Ldl

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ARGININE; CD36 RECEPTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG; 2,4-THIAZOLIDINEDIONE; CD36 ANTIGEN;

ATHEROSCLEROSIS; HUMAN; PATHOGENESIS; PROTEIN EXPRESSION; PROTEIN STRUCTURE; REVIEW; CHEMISTRY; GENE EXPRESSION REGULATION; GENETICS; PHYSIOLOGY;

ARGININE; ATHEROSCLEROSIS; CD36 ANTIGENS; GENE EXPRESSION REGULATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; THIAZOLIDINEDIONES;

EID: 85026485067     PISSN: 18995276     EISSN: 24512680     Source Type: Journal    
DOI: 10.17219/acem/62325     Document Type: Review

References (55)

1. Febbraio M, Hajjar DP, Silverstein RL. CD36: A class B scavengerreceptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism. J Clin Invest. 2001;108:785-791.
2. Kuliczkowska-Paksej J, Bednarek-Tupikowska G, Paksej R, Filus A.Receptor CD36-wystpowanie, regulacja ekspresji oraz rola w patogeneziemiadycy. Cz I. Postepy Hig Med Dosw. 2006;60:142-151.
3. Ohgami N, Nagai R, Ikemoto M, Arai H, Kuniyasu A, Horiuchi S, Nakayama H. CD36, a member of the class B scavenger receptorfamily. As a receptor for advanced glycation end products. J Biol Chem. 2001;276(5):3195-3202.
4. Silverstein RL, Febbraio M. CD36, a scavenger receptor involvedin immunity, metabolism, angiogenesis and behavior. Sci Signal. 2009;2(72): 3.
5. Greenwalt DE, Lipsky RH, Ockenhouse CF, Ikeda H, Tandon NN, Jamieson GA. Membrane glycoprotein CD36: A review of its roles inadherence, signal transduction, and transfusion medicine. Blood. 1992;80:1105-1115.
6. Nicholson AC. Exspression of CD36 inmacrophages and atherosclerosis.The role of lipid regulation of PPAR signaling. Trends Cardiovasc Med. 2004;14:8-12.
7. Li W, Febbraio M, Reddy SP, Yu DY, Yamamoto M, Silverstein RL.CD36 participates in a signaling pathway that regulates ROS formationin Marine VSMCs. J Clin Invest. 2010;120(11):3996-4006.
8. Harasim E, Kalinowska A, Stpek T, Chabowski A. Udzia biaektransportujcych (FAT/CD36, FABPpm, FATP) w metabolizmielipidow w miniach szkieletowych. Postepy Hig Med Dosw. 2008;62:433-441.
9. Kalinowska A, Harasim E, ukaszuk B, Chabowski A. Biaka transportujcekwasy tuszczowe a metabolizm lipidow w miniu sercowym.Czynniki Ryzyka. 2009;4:43-49.
10. Febbraio M, Guy E, Silverstein RL. Stem cell transplantation revealsthat absence of macrophage CD36 is protective against atherosclerosis.Arterioscler Thromb Vasc Biol. 2004;24:2333-2338.
11. Silverstein RL, Li W, Park YM, Rahaman SO. Mechanism of cell signalingby the scavenger receptor CD36: Implications in atherosclerosisand thrombosis. Trans Am Clin Climatol Assoc. 2010;121:206-220.
12. Febbraio M, Podrez EA, Smith JD, et al. Targeted disruption of theclass B scavenger receptor CD36 protects against atheroscleroticlesion development in mice. J Clin Invest. 2000;105:1049-1056.
13. Kennedy DJ, Kuchibhotla S, Westfall KM, Silverstein RL, Morton RE, Febbraio M. A CD36-dependent pathway enhances macrophageand adipose tissue inflammation and impairs insulin signalling.Cardiovasc Res. 2011;89:485-486.
14. Kuda O, Jenkins CM, Skinner JR, Moon SH, Su X, Gross RW, Abumrad NA. CD36 protein is involved in store-operated calcium flux, phospholipase A2 activation, and production of prostaglandin E2. J Biol Chem. 2011;286(20):17785-17795.
15. Nakata A, Nakagawa Y, Nishida M, et al. CD36, a novel receptor foroxidized lowdensity lipoproteins, is highly expressed on lipid-ladenmacrophages in human atherosclerotic aorta. Thromb Vasc Biol. 1999;19:1333-1339.
16. Rios FJ, Ferracini M, Pecenin M, Koga MM, Wang Y, Ketelhuth DF, Jancar S. Uptake of ox LDL and IL-10 production by macrophagesrequires PAFR and CD36 recruitment into the same lipid rafts. PLoSOne. 20138(10):e76893. doi: 10.1371.
17. Han S, Sidell N. Peroxisome-proliferator-activated-receptor gamma(PPARgamma) independent induction of CD36 in THP-1 monocytesby retinoic acid. Immunology. 2002;106:53-59.
18. Moore KJ, Kunjathoor VV, Koehn SL, et al. Loss of receptor-mediatedlipid uptake via scavenger receptor A or CD36 pathways doesnot ameliorate atherosclerosis in hyperlipidemic mice. J Clin Invest. 2005;115(8):2192-2201.
19. Yuasa-Kawase M, Masuda D, Yamashita T, et al. Patients with CD36deficiency are associated with enhanced atherosclerotic cardiovasculardiseases. J Atheroscler Thromb. 2012;19(3):263-275.
20. Xie S, Lee YF, Kim E, et al. TR4 nuclear receptor functions as afattyacid sensor to modulate CD36 expression and foam cell formation.Proc Natl Nacad Sci USA. 2009;106(32):13353-13358.
21. Han J, Hajjar DP, Tauras JM, Nicholson AC. Cellular cholesterol regulatesexpression of the macrophage type B scavenger receptor, CD36. J Lipid Res. 1999;40:830-838.
22. Zhao SP, Yang J, Li J, Dong SZ, Wu ZH. Effect of niacin on LXRalpha and PPARgamma expression and HDL-induced cholesterol efflux in adipocytesof hypercholesterolemic rabbits. Int J Cardiol. 2008;124:172-178.
23. Zhong Q, Zhao S, Yu B, et al. High-density lipoprotein increases theuptake of oxidized low density lipoprotein via PPAR/CD36 pathwayin inflammatory adipocytes. Int J Biol Sci. 2015;11(3):256-265.
24. Han J, Hajjar DP, Zhou X, Gotto AMJr, Nicholson AC. Regulationof peroxisome proliferator-activated receptor-gamma-mediatedgene expression. A new mechanism of action for high density lipoprotein.J Biol Chem. 2002;277:23582-23586.
25. Chabowski A, Coort SL, Calles-Escandon J, et al. Insulin stimulatesfatty acid transport by regulating expression of FAT/CD36 but not FABPpm. Am J Physiol Endocrinol Metab. 2004;287(4):E781-E789.
26. Kuliczkowska-Paksej J, Bednarek-Tupikowska G, Paksej R, Filus A.Wpyw cukrzycy i insulinoopornoci na ekspresj receptora CD36.Cz II. Udzia receptora CD36 w patomechanizmie powikacukrzycy. Postepy Hig Med Dosw. 2006;60:152-162.
27. Yanai H, Chiba H, Morimoto M, Jamieson GA, Matsuno K. Type I CD36 deficiency in humans is not associated with insulin resistancesyndrome. Thromb Haemost. 2000;83(5):786.
28. Bekkering S, Quintin J, Joosten LA, van der Meer JW, Netea MG, Riksen NP. Oxidized low-density lipoprotein induces long-term proinflammatorycytokine production and foam cell formation via epigeneticreprogramming of monocytes. Arterioscler Thromb Vasc Biol. 2014;34(8);1731-1738.
29. Sui Y, Park SH, Helsley RN, et al. Bisphenol A increases atherosclerosisin pregnane X receptor-humanized Apo E deficient mice. J Am Heart Assoc. 2014;3(2):e000492. doi: 10.1161/JAHA.113.000492.
30. Huang JT, Welch JS, Ricote M, et al. Interleukin-4-dependent productionof PPAR-g ligands in macrophages by 12/15-lipoxygenase.Nature. 1999;400:378-382.
31. Han J, Hajjar DP, Tauras JM, Feng J, Gotto AM, Nicholson AC. Transforminggrowth factor-beta 1 (TGF-beta 1) and TGF-beta 2 decreaseexpression of CD36, the type B scavenger, through mitogen-activatedprotein kinase phosphorylation of peroxisome proliferatoractivatedreceptor-gamma. J Biol Chem. 2000;275:1241-1246.
32. Nakagawa T, Nozaki S, Nishida M, et al. Oxidized LDL increasesand interferongamma decreases expression of CD36 in humanmonocyte-derived macrophages. Arterioscler Thromb Vasc Biol. 1998;18:1350-1357.
33. Chu EM, Tai DC, Beer JL, Hill JS. Macrophage heterogeneity and cholesterolhomeostasis: Classically-activated macrophages are associatedwith reduced cholesterol accumulation following treatmentwith oxidized LDL. Biochim Biophys Acta. 2012;1831(2):378-386.
34. Zernecke A, Bot I, Djalali-Talab Y, et al. Protective role of CXC receptor4/CXC ligand 12 unveils the importance of neutrophils in atherosclerosis.Circ Res. 2008;102:209-217.
35. Baetta R, Corsini A. Role of polymorphonuclear neutrophils in atherosclerosis:current state and future perspectives. Atherosclerosis. 2010;210(1):1-13.
36. Quinn KL, Henriques M, Tabuchi A, et al. Human neutrophil peptidesmediate endothelial-monocyte interaction, foam cell formation, and platelet activation. Arterioscler Thromb Vasc Biol. 2011;31(9):2070-2079.
37. Sui Y, Xu J, Rios-Pilier J, Zhou C. Deficiency of PXR decreases atherosclerosisin apo E-deficient mice. J Lipid Res. 2011;52(9):1652-1659.
38. Rios FJ, Ferracini M, Pecenin M, et al. Uptake of ox LDL and IL-10 productionby macrophages requires PAFR and CD36 recruitment intothe same lipid rafts. PLoS One. 2013;8(10):e76893. doi: 10.1371.
39. Mendez-Barbero N, Esteban V, Villahoz S, et al. A major rolefor RCAN1 in atherosclerosis progression. EMBO Mol Med. 2013;5(12):1901-1917.
40. Lindgren A, Levin M, Rodrigo Blomqvist S, et al. Adiponectinreceptor 2 deficiency results in reduced atherosclerosis in the brachiocephalicartery in apolipoprotein e deficient mice. PLoS One. 2013;8(11):e80330. doi: 10.1371.
41. Xia F, Li R, Wang C, et al. IRGM1 regulates oxidized LDL uptake bymacrophage via actin-dependent receptor internalization duringatherosclerosis. Sci Rep. 2013;3:1867. doi: 10.1038.
42. Han J, Zhou X, Yokoyama T, Hajjar DP, Gotto AM, Nicholson AC.Pitavastation downregulates expression of the macrophage type Bscavenger receptor, CD36. Circulation. 2004;17:790-796.
43. Piechota M, Banaszewska A, Dudziak J, Slomczynski M, Plewa R.Highly upregulated expression of CD36 and MSR1 in circulatingmonocytes of patients with acute coronary syndromes. Protein J. 2012;31(6):511-518.
44. Fukuda K, Matsumura T, Senokuchi T, et al. Statins meditate antiatheroscleroticaction in smooth muscle cells by peroxisome proliferator-activated receptor-A ctivation. Biochem Biophys Res Commun. 2015;457(1):23-30.
45. Tontonoz P, Nagy L, Alvares JG, Thomazy VA, Evans RM.PPARpromotes monocyte/macrophage differentiation anduptake of oxidized LDL. Cell. 1998;93:241-252.
46. Lehman JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinityligand for peroxisome proliferator-activated receptor gamma(PPAR gamma). J Biol Chem. 1995;270(22):12953-12956.
47. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated recptor-is a negative regulator of macrophageactivation. Nature. 1998;391:79-82.
48. Komatsu A, Node K. Effects of PPARgamma agonist on dyslipidemiaand atherosclerosis. Nihon Rnsho. 2010;68(2):294-298.
49. Chinetti G, Lestavel S, Bocher V, et al. PPAR-A nd PPAR-A ctivatorsinduce cholesterol removal from human macrophage foamcell through stimulation ABCA1 pathway. Nat Med. 2001, 7(1):53-58.
50. Xin Wang, Jianming Wei, Lijian Pan, Yijun Shi, Haihong Lin, Hui G.The role of CD36 in the effect of arginine in atherosclerotic rats.Med Sci Monit. 2015;21:1494-1499.
51. Nozaki S, Kashiwagi H, Yamashita S, et al. Reduced uptake of oxidizedlow density lipoproteins i monocyte-derived macrophagesfrom CD36-deficient subjects. J Clin Invest. 1995;96:1859-1865.
52. Magwenzi S, Woodward C, Wraith KS, et al. Oxidized LDL activatesblood platelets through CD36/NOX2-mediated inhibition ofthe c GMP/protein kinase G signaling cascade. Blood. 2015;125(17):2693-2703.
53. Areschoug T, Gordon S. Scavenger receptors: Role in innate immunityand microbial pathogenesis. Cel Microbiol. 2009;11(8):1160-1169.
54. Dawson DW, Pearce SFA, Zhong R, Silverstein RL, Bouck NP. CD36mediates the inhibitory effects of thromobospondin-1 on endothelialcells. J Cell Biol. 1997;138:707-717.
55. Wu J, He Z, Gao X, et al. Oxidized high-density lipoprotein impairsendothelial progenitor cells' function by activation of CD36-MAPKTSP-1 pathways. Antioxid Redox Signal. 2015;22(4):308-324.